Stephen P. Newman
University of Nottingham
PharmacokineticsBiomedical engineeringIntensive care medicineChemistryIn vivoAsthmaBudesonideInhalationDry-powder inhalerLungDrug deliveryDrugInhalerMetered-dose inhalerBronchodilatorNuclear medicineRadionuclide imagingLung depositionGamma scintigraphyAnesthesiaChromatographyMedicineCrossover studyPharmacology
62Publications
27H-index
2,427Citations
Publications 79
Newest
#1Stephen P. NewmanH-Index: 27
#2Hak-Kim Chan (USYD: University of Sydney)H-Index: 74
Abstract Conventional in vitro tests to assess the aerodynamic particle size distribution (APSD) from inhaler devices use simple right-angle inlets (“mouth-throats”, MTs) to cascade impactors, and air is drawn through the system at a fixed flow for a fixed time. Since this arrangement differs substantially from both human oropharyngeal airway anatomy and the patterns of air flow when patients use inhalers, the ability of in vitro tests to predict in vivo deposition of pharmaceutical aerosols has...
3 CitationsSource
Abstract The repurposing of drug delivery by the pulmonary route has been applied to treatment and prophylaxis of an increasingly wide range of respiratory diseases. Repurposing has been most successful for the delivery of inhaled bronchodilators and corticosteroids in patients with asthma and chronic obstructive pulmonary disease (COPD). Repurposing utilizes the advantages that the pulmonary route offers in terms of more targeted delivery to the site of action, the use of smaller doses, and a l...
29 CitationsSource
Introduction: The inhaled route has many advantages, but requires the patient to use, and to master the use of, an inhaler device. Poor inhaler technique and non-adherence to therapy lead to a highly variable lung dose in clinical practice, with subsequent loss of clinical efficacy and wastage of economic resources. Areas covered: This paper discusses problems of poor inhaler technique, non-adherence to inhaler therapy, other issues relating to the precision of dose delivery, the consequences of...
34 CitationsSource
#1Stephen P. NewmanH-Index: 27
#2William D. Bennett (UNC: University of North Carolina at Chapel Hill)H-Index: 40
Last. Kirby L. Zeman (UNC: University of North Carolina at Chapel Hill)H-Index: 31
view all 14 authors...
Abstract Two-dimensional (2D or planar) imaging with 99mTc radiolabels enables quantification of whole-lung and regional lung depositions for orally inhaled drug products. This article recommends standardized methodology for 2D imaging studies. Simultaneous anterior and posterior imaging with a dual-headed gamma camera is preferred, but imaging with a single-headed gamma camera is also acceptable. Correction of raw data for the effects of gamma ray attenuation is considered essential for accurat...
58 CitationsSource
#1John S. Fleming (University Hospital Southampton NHS Foundation Trust)H-Index: 25
#2Dale L. Bailey (RNSH: Royal North Shore Hospital)H-Index: 60
Last. Stephen P. NewmanH-Index: 27
view all 7 authors...
Abstract Single-photon emission computed tomography (SPECT) can be used to measure the three-dimensional (3D) distribution of inhaled aerosol deposition in the lungs. This is of value in evaluating and optimizing drug delivery by inhalation. 3D imaging has the advantage over planar scintigraphy of giving better data on the distribution of deposition within the lung. There are a variety of different methods of acquisition and analysis of the data, which makes interpretation of results difficult t...
30 CitationsSource
#1Sunalene G. Devadason (UWA: University of Western Australia)H-Index: 24
#2Hak-Kim Chan (USYD: University of Sydney)H-Index: 74
Last. Glyn Taylor (Cardiff University)H-Index: 24
view all 8 authors...
Radiolabeling of inhaler formulations for imaging studies is an indirect method of determining lung deposition and regional distribution of drug in human subjects. Hence, ensuring that the radiotracer and drug exhibit similar aerodynamic characteristics when aerosolized, and that addition of the radiotracer has not significantly altered the characteristics of the formulation, are critical steps in the development of a radiolabeling method. The validation phase should occur during development of ...
24 CitationsSource
#1Beth L. Laube (JHUSOM: Johns Hopkins University School of Medicine)H-Index: 31
#2Timothy E. Corcoran (University of Pittsburgh)H-Index: 24
Last. Stephen P. NewmanH-Index: 27
view all 6 authors...
5 CitationsSource
#1Stephen P. NewmanH-Index: 27
#2John S. Fleming (University of Southampton)H-Index: 25
Introduction: Both the total amount of drug deposited in the lungs (whole lung deposition) and the amount deposited in different lung regions (regional lung deposition) are potentially important factors that determine the safety and efficacy of inhaled drugs. Radionuclide imaging is well established for quantifying the whole lung deposition of inhaled drugs, but the assessment of regional lung deposition is less straightforward, because of the complex nature of the lung anatomy. Areas covered: T...
26 CitationsSource
#1Dennis O'Connor (Boehringer Ingelheim)H-Index: 4
#2Wallace P. AdamsH-Index: 16
Last. Sandra Suarez SharpH-Index: 2
view all 23 authors...
Abstract In April 2010 a workshop on the “Role of Pharmacokinetics in Establishing Bioequivalence for Orally Inhaled Drug Products” was sponsored by the Product Quality Research Institute (PQRI) in coordination with Respiratory Drug Delivery (RDD) 2010. The objective of the workshop was to evaluate the current state of knowledge and identify gaps in information relating to the potential use of pharmacokinetics (PK) as the key indicator of in vivo bioequivalence (BE) of locally acting orally inha...
32 CitationsSource
#1Thomas F. MeyerH-Index: 119
#2Peter ReitmeirH-Index: 1
Last. Stephen P. NewmanH-Index: 27
view all 8 authors...
Summary Background Lung mucociliary clearance is impaired in patients with chronic obstructive pulmonary disease (COPD). Treatment guidelines recommend that patients with COPD receive maintenance therapy with long-acting beta-agonists and anticholinergic agents. Methods Twenty-four patients with mild to moderate COPD received formoterol (12 μg, twice daily from Turbuhaler ® dry powder inhaler (DPI)) or tiotropium (18 μg, once daily from Handihaler ® DPI) for 14 days. They also received single do...
19 CitationsSource